M&G plc (MNG.L) today: Barclays lifts price target to 310p — all the news on 18 November 2025

M&G plc (MNG.L) today: Barclays lifts price target to 310p — all the news on 18 November 2025

London, 18 November 2025 — The key development for FTSE‑100 asset manager and insurer M&G plc today is a broker move from Barclays, which raised its price target to 310p (from 295p) and maintained an ‘Overweight’ rating in a sector‑wide note published this morning at 09:03. The same report also adjusted targets across UK insurance peers, underscoring a constructive stance on the group. Shares Magazine


What changed today

  • Broker action: Barclays’ new 310p target implies upside from last night’s close and keeps M&G in its preferred list among UK life and savings groups. In the same sweep, Barclays raised targets for Legal & General and Prudential and tweaked others across the space, framing a supportive backdrop for the sector. Shares Magazine

Shareholder register watch (latest filings)

  • Morgan Stanley stake moves: The latest TR‑1 filings show Morgan Stanley reduced its total voting interest in M&G to 5.77% (5.769458%) as of 12 November 2025 (notified 14 November), down from 6.12% (6.119767%) previously reported for 10 November. These disclosures were carried on the market’s RNS feed in recent days. Investegate

Operating momentum that’s informing the calls

  • Q3 update (5 Nov): M&G reported £1.5bn of net inflows from external clients into Asset Management in Q3 and said Asset Management AUMA stood at £335bn, with both Institutional and Wholesale franchises in net inflow. M&G
  • Group lens: Reuters’ read‑through of the trading statement highlighted group assets under management rising to £365bn and £1.8bn of open‑business net inflows in the quarter, pointing to momentum into year‑end. Reuters

Strategy backdrop: the Dai‑ichi partnership

  • 15% strategic stake: In May, Japanese insurer Dai‑ichi Life agreed to acquire a 15% holding in M&G alongside a multi‑year distribution and product partnership expected to drive at least $6bn of flows into M&G strategies over five years and to include a Dai‑ichi board seat at M&G when the threshold is reached. The deal is intended to deepen M&G’s access to Asian clients and private‑markets opportunities. Reuters

Where the shares stand

  • Latest close before today’s note: M&G closed at 266.0p on Monday, 17 November 2025, on volume of about 6.6m shares, per exchange data. Yahoo Finance
  • Range context: As of Friday’s close, the stock was 3.8% below its 52‑week high of 279p (3 September 2025), according to MarketWatch’s running performance recap. MarketWatch

Other recent analyst colour

  • Berenberg upgraded M&G to ‘Buy’ in October and lifted its target to 342p, citing improving cash and capital metrics and rising dividend visibility across UK life insurers. RBC reiterated ‘Sector perform’ with a 265p target on 10 November. These calls frame today’s Barclays move within a broader sequence of constructive coverage. Lloydsbank

What to watch next

  1. Further TR‑1 updates: Additional notifications around major holdings (up or down) have been frequent in November; any new RNS could influence sentiment. Investegate
  2. Execution on inflows: Whether Q3’s external‑client momentum persists into Q4 will be key for fee revenue trajectory. M&G
  3. Dai‑ichi tie‑in milestones: Progress toward the full 15% stake and initial co‑manufactured products or distribution wins in Japan/Asia. Reuters

Bottom line for 18 November 2025

Today’s newsflow is led by Barclays lifting M&G’s target to 310p and reiterating ‘Overweight’, reinforcing constructive sell‑side sentiment that has built since the Q3 update and the strategic tie‑up with Dai‑ichi. With external inflows improving and the shareholder register active, investors will watch for confirmation that momentum can carry through the fourth quarter. Reuters

Disclosure: This article is for information only and does not constitute investment advice.

Stock Market Today

  • Collegium Pharmaceutical (COLL) Valuation and Share Price Analysis Amid Recent Swings
    January 18, 2026, 10:26 PM EST. Collegium Pharmaceutical (NasdaqGS:COLL) saw a 31% gain over three months but dipped 7% in the past month, with its 1-year total shareholder return at 36.7%. Trading at $45.60, the stock appears undervalued compared to a fair value estimate of $53.17, boosted by margin expansion and earnings growth tied to products like Jornay PM. However, the price-to-earnings ratio of 24.7x surpasses industry and peer averages, signaling possible valuation risks if growth slows. Investors face uncertainties including generic competition and sales scaling of flagship products. Careful analysis is necessary to balance the upside potential against these risks in this specialty pharmaceutical player.
National Grid (NG.L) Today—18 November 2025: New CEO Zoë Yujnovich takes charge, ex‑dividend this week, AI power plans sharpen focus on grid capacity
Previous Story

National Grid (NG.L) Today—18 November 2025: New CEO Zoë Yujnovich takes charge, ex‑dividend this week, AI power plans sharpen focus on grid capacity

Gold Hits $4,000 as AI Frenzy Pushes Stocks Near Record – Boom or Bust Ahead?
Next Story

Gold Price Today, 18 November 2025: Spot Gold Hovers Near $4,050 as Fed Jitters Extend Losing Streak

Go toTop